Literature DB >> 2765115

Multiple forms of 17 beta-hydroxysteroid oxidoreductase in human breast tissue.

G H Tait1, C J Newton, M J Reed, V H James.   

Abstract

17 beta-Hydroxysteroid oxidoreductase, the enzyme that catalyses the interconversion of oestradiol and oestrone, is known to be present in human breast tissue. However, it is not known whether one or more forms of the enzyme is present. Homogenates of breast adipose tissue and breast glandular tissue were fractionated and fractions assayed in the oxidative direction with NAD+ and NADP+ as coenzymes, and in the reductive direction with NADH and NADPH as coenzymes. Ultracentrifugation of homogenates showed that there was membrane-bound activity and soluble activity. The soluble activity was due to a number of forms of the enzyme with different molecular weights, three in breast adipose tissue and two in breast glandular tissue, as shown by fractionation with (NH4)2SO4 followed by chromatography on Sephadex G-200. The forms of the enzyme isolated differed in their affinities for substrates and coenzymes and in the relative rates at which they catalysed the oxidative and reductive reactions. Preliminary experiments with breast tumours showed that they also contained membrane-bound activity and more than one soluble form of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2765115     DOI: 10.1677/jme.0.0020071

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  7 in total

1.  Purification and properties of oestradiol 17 beta-dehydrogenase extracted from cytoplasmic vesicles of porcine endometrial cells.

Authors:  J Adamski; B Husen; F Marks; P W Jungblut
Journal:  Biochem J       Date:  1992-12-01       Impact factor: 3.857

Review 2.  Estrogen metabolism as a regulator of estrogen action in the mammary gland.

Authors:  M Miettinen; V Isomaa; H Peltoketo; D Ghosh; P Vihko
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

3.  Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer.

Authors:  P E Lønning; S I Helle; D C Johannessen; D Ekse; H Adlercreutz
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Inhibitory effects of medroxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (E1)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.

Authors:  S Li; C Lévesque; C S Geng; X Yan; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

5.  Inhibitory effect of a steroidal antiestrogen (EM-170) on estrone-stimulated growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.

Authors:  F Labrie; S Li; C Labrie; C Lévesque; Y Mérand
Journal:  Breast Cancer Res Treat       Date:  1995-03       Impact factor: 4.872

6.  Dehydroepiandrosterone and estrone 17-ketosteroid reductases in MCF-7 human breast cancer cells.

Authors:  J H MacIndoe; M Hinkhouse; G Woods
Journal:  Breast Cancer Res Treat       Date:  1990-10       Impact factor: 4.872

7.  Alteration of oestradiol metabolism in myc oncogene-transfected mouse mammary epithelial cells.

Authors:  N T Telang; F Arcuri; O M Granata; H L Bradlow; M P Osborne; L Castagnetta
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.